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INTRODUCTION
Aristolochic acid nephropathy (AAN) is a unique
nephropathy characterized by rapidly progressive
interstitial fibrosis and urothelial cancer. It is related to
the prolonged intake of Chinese herbal remedies
containing the nephrotoxic and carcinogenic
aristolochic acid (AA).
AAN was recognized and reported in the Chinese
and English literature in the early 1960s. In 1963, Peters
and Hedwall observed the loss of concentrating ability
of the kidney as a result of intoxication with AA [1].
Ten cases of acute renal failure, caused by overdose of
Caulis Aristolochiae Manshuriensis ( ), were
reported in China between 1964 and 1988 [2–5].
However, there has been a delay in the appreciation of
these findings until the early 1990s [6].
In the early 1990s, a weight loss clinic in Belgium
formulated a “slimming regimen” consisting of a
cocktail of drugs and various herbal powders including
Radix Stephaniae Tetrandrae ( ) and Cortex
Magnoliae Officinalis (). Between 1990 and 1992,
about 1,700 users were exposed to the product. More
than 100 patients subsequently developed severe renal
failure, about half of whom required a renal transplant
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[7]. End-stage kidney failure occurred 3 months to 7
years after the patients had stopped taking the weight
loss pills. Renal biopsy samples showed extensive
interstitial fibrosis without glomerular lesions [8].
Urothelial malignancies were common [9]. Based on
the clinical evidence and involvement of Chinese herbs,
clinicians in Belgium coined the term, “Chinese herb
nephropathy” to describe the phenomenon.
But was the first to suggest that one of the herbs,
Radix Stephaniae Tetrandrae ( ), could have
been inadvertently replaced by AA containing
Aristolochiae Fangchi ( ) [10]. Phytochemical
analysis of 12 different samples of Radix Stephaniae
Tetrandrae delivered to Belgium from 1990 to 1992
showed that only one sample corresponded to
Stephania species, whereas the others were probably
Aristolochia species [11]. The causal role of AA in
the Belgian epidemic was established later by the
detection of AA DNA adducts in kidneys removed
from patients with Chinese herb nephropathy [12].
These adducts are specific markers of exposure to
aristolochic acids [13,14]. Furthermore, AA given
alone to rabbits induced similar renal and urothelial
lesions [15]. The term AAN was proposed to replace
Chinese herb nephropathy [16].
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Subsequently, more reports linking AA to
nephrotoxicity were reported worldwide, resulting in
the ban of AA-containing herbs and products in many
countries [17–22].
AA-CONTAINING HERBS
AA includes a mixture of structurally related
nitrophenanthrene carboxylic acids produced by the
Aristolochiaceae family,  with 8-methoxy-6-
nitrophenanthro-(3,4-d)-1,3-dioxolo-5-carboxylic acid
(AAI) and its 8-desmethoxylated form (AAII)
representing the major constituents of these plants [23].
Aristolochia plants and their extracts have been used
in traditional Chinese medicine (TCM) to remove heat,
relieve pain, dispel wind and promote diuresis [24].
Examples of frequently encountered AA-containing
herbs include Caulis Aristolochiae Manshuriensis
( ), Radix Aristolochiae Fangchi ( ), Fructus
Aristolochiae ( ), Radix Aristolochiae ( )
and Herba Aristolochiae ( ). The amount of AA
varies between species, and Caulis Aristolochiae
Manshuriensis contains the highest amount [25]. Low
levels of AA have also been reported in Herba Asari
() [26].
ETIOLOGY AND PATHOLOGY
Several studies have established that AA is strongly
nephrotoxic [15,27–29], genotoxic [30,31], and
carcinogenic in humans and rodents [9,13,32,33]. AAI
was found to be more toxic than AAII, and other
structural analogs either have less overall toxicity or
no toxicity [34].
AAN is recognized as a separate entity of renal
tubulointerstitial disease. The renal pathology is
characterized by extensive interstitial fibrosis and
tubular atrophy, which generally decreases in intensity
from the outer to the inner cortex. The glomeruli are
usually spared, but global or peripheral sclerosis of
glomeruli, decreasing from the outer to the inner cortex,
including the columns of Bertin has been reported.
Immune deposits are not a feature. Endothelial cell
swelling is often apparent with consequent thickening
of interlobular and afferent arterioles [35–38].
Urothelial cancer of the upper urinary tract associated
with urothelial atypia is frequently found in AAN [39].
The nephrotoxic effect of AA is dose dependent
[28,40]. AA has been shown to be toxic to renal tubular
epithelium and to induce apoptosis [41–43]. However,
the underlying mechanism driving the progression of
renal interstitial fibrosis remains unclear. There is
markedly injured peritubular capillary in the renal
interstitium from patients with acute AAN [44].
The subsequent ischemia and hypoxia may contribute
to the fibrosis [45].
AA is among the most potent 2% of known
carcinogens [46]. The cumulative dose of aristolochia
was a significant risk factor for urothelial carcinoma
[9]. Mutagenic and carcinogenic effects of AA are
associated with the formation of AA-DNA adducts [47].
Metabolic activation of AA is essential to produce the
DNA-binding species. AA is activated by different
enzymes, including prostaglandin H synthase, the most
abundant peroxidase present in the kidney and ureter
[48]. Therefore, prostaglandin H synthase could be one
of the most important activators of AA to toxic and
carcinogenic metabolites in the target tissues of AAN
patients [49]. On metabolic activation, AA binds
covalently to the exocyclic amino group of DNA purine
nucleotides, leading eventually to the formation of DNA
adducts [50]. The most abundant adduct is the AAI-
adenine adduct, which is a mutagenic lesion leading to
A to T transversion in DNA during replication in vitro
[14,51,52]. The specific DNA adduct remains in tissues
for an extensive period and suggests non-reparable
genomic lesions [9].
Urothelial carcinoma as well as urothelial atypia
were associated with the overexpression of the p53
protein in Belgian AAN patients, suggesting that the p53
gene is mutated in AA-associated urothelial cancer [39].
This conclusion is further supported by the formation of
AA-DNA adducts and the characteristic A to T
transversion mutation in the human p53 gene [29,53].
It is interesting to note that only a small fraction of
the patients who followed the slimming regimen in
Belgium developed AAN [54]. A few cases with AAN
showed familial aggregation [44]. Predisposition
towards nephrotoxicity and carcinogenicity may be
genetically determined [55]. The effect of the genetic
polymorphism on AA metabolism remains to be
evaluated.
When AAN is  suspected ,  b iopsy or  per
transplantation nephrectomy should be seriously
considered: the histologic picture is highly suggestive
and the detection of AA-DNA adducts is confirmatory
[56]. The association of interstitial fibrosis with
urothelial atypia and malignancy is also reminiscent of
analgesic nephropathy. The hallmark of classic
analgesic nephropathy is papillary necrosis with
associated interstitial fibrosis and chronic inflammatory
cell infiltrates, a feature that is absent in AAN [57].
CLINICAL FEATURES
AAN has two distinctive clinical syndromes. The
classical type is subacute renal failure associated with
normal or mildly elevated blood pressure, low-grade
proteinuria, glycosuria and insignificant urinary
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sediments. Anemia was more severe than expected for
the degree of renal failure, probably as a result of early
destruction of peritubular cells producing erythropoietin
[58]. Renal function deteriorated rapidly and
progressively in most patients despite discontinuation
of the herbal medicines [59]. The rate of progression
of renal failure is significantly related to the duration
of AA-containing herb use and the cumulative dose [40,
58]. Corticosteroid therapy has been claimed to slow
the progression of renal failure [60]. A recent study in
rats revealed that angiotensin II receptor blocker shows
a protective effect on renal interstitial fibrosis induced
by AA-containing herbs [61].
The other variant, Fanconi’s syndrome, has been
mostly reported in Asian countries [62–66]. It is
characterized by proximal tubular dysfunction and
slowly progressive renal insufficiency which is often
reversible [67,68]. The aminoaciduria showed
predominance of imino acid [69]. There was no
subsequent development of urothelial carcinoma
reported in association with the Fanconi’s syndrome
variant [70]. The reason that AA causes two clinical
syndromes remains elusive. The amount of ingested
AA, difference in AA-containing constituents and racial
differences are possible factors [62].
In addition to renal toxicity, AAN is also associated
with the development of urothelial carcinomas in 40–
46% of patients [9]. Urothelial cancer seems to be a
late complication since most cases were detected in
patients with end-stage renal failure. Nevertheless,
invasive urothelial carcinoma after exposure to AA-
containing herbs may occur without severe renal failure
[38].
AA POISONINGS IN CHINA AND HONG KONG
Initially, there was a lack of consensus on the toxicity
of AA-containing herbs in China. It was suggested that
the renal disease described in Belgium was the result
of inappropriate use of Chinese herbs by physicians
who were not trained in TCM rather than the toxicity
of Chinese herbs per se [71]. Nevertheless, renal
toxicity occurred even when the herbs were used in
accordance with TCM guidelines. Two series of 58 and
51 cases of AAN were reported in China in 2001;
patients had taken different Chinese herbal medicines
containing AA and developed nephropathy similar to
the one reported in Belgium [72,73]. Many of them
took the liver tonic Longdan Xieganwan ( !"),
a  composi te  formula that  contained Caul is
Aristolochia Manshuriensis ( ) as the major
ingredient. Presence of other ingredients in the formula
did not prevent AA toxicity [74]. With more and more
cases reported, control measures on the use of AA-
containing herbs were introduced in China in 2003.
Recently in China, more than 100 patients have
launched legal action against the manufacturer of
Longdan Xieganwan, arguing that they sold it despite
knowledge of the dangers [75].
While AAN has been reported in many countries,
there was no local case reported in Hong Kong until
2004 [76]. Five cases of AA poisoning have been
identified (Table 1). Four of them were confirmed in
our laboratory by the detection of AA in the herbal
products concerned. One patient developed progressive
renal failure and bladder cancer after taking the herbs
for 6 months [77]. We found that the non-toxic Herba
Solani Lyrati () had been mixed up with the AA-
containing Herba Aristolochia Mollissemae ( ).
Both herbs are furry in appearance and share a common
name ( ) that means furry. The erroneous
substitution was found to have occurred at the
wholesaler level and subsequently led to the discovery
of more AAN cases. Our findings contributed to the
withdrawal of the AA-containing herbs and products
by the local health authority in Hong Kong in June 2004
[77].
PREVENTION OF AA POISONINGS
Most AAN cases are associated with prolonged usage
or acute overdose. Few patients got the disease after
taking therapeutic dosage for a short period [72]. There
is thus no consensus on what constitutes a safe dose
[74]. Some advocate a total ban on all AA-containing
herbs from the pharmaceutical market [78]. As
expected, the scope and depth of control measures on
AA-containing herbs vary among countries. Table 2 is
a summary of the ban condition in China, Hong Kong
and Taiwan [79].
Since June 2004, the importation and sale of
Aristolochia Linn ( !) herbs and products have
been prohibited in Hong Kong. Regarding the herb
Herba Asari (), only the root can be used [80].
According to TCM practice, Herba Asari alleviates
pain and dispels cold winds. Therefore, it is a common
ingredient in traditional formulae. There is a paucity
of information on the toxicity of Herba Asari. According
to a recent survey, nine species of Herba Asari in the
market were found to contain variable amounts of AAI.
In general, only small amounts of AA were present.
Nevertheless, AA contents in some Asarum species
were comparable to that of Caulis Aristolochiae
Manshuriensis ( ) [25,81]. Small amounts of AA
are also present in the root of Herba Asari [82].
Recently, there was a report of AAN in a patient who
had been taking patent herbal remedies containing
Herba Asari for 4 months. It was suggested that Herba
Asari containing aristolochic acid should also be
forbidden for use [83].
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CONCLUSION
AAN has been well documented in the past 10 years.
Use of AA-containing herbs is prohibited in many
countries. This action has no doubt reduced the
incidence of AAN. However, the public may still be at
risk. It was found that AA-containing products were
still available in the market after the ban [84–87]. The
risk is exemplified by the latest report of AAN
associated with the use of Herba Asari. Despite the
relatively small amounts of AA present, it is uncertain
if cumulative toxicity could occur after prolonged or
intermittent use of Herba Asari. More information and
studies are required before the risk can be fully
validated. Patients with underlying renal disease are
particularly susceptible to AA toxicity [76,88,89]. It is
prudent for renal patients to avoid AA-containing herbs.
We believe that AAN will persist as long as AA-
containing herbs are available for use. Unexplained
renal failure together with interstitial fibrosis should
alert a physician to the possibility of AAN. A
multidisciplinary team of experts should be made
available to provide advice to frontline healthcare
professionals [90].
AAN is a terrible example of what can go wrong
when quality control measures of herbal products are
insufficient or not observed. It also highlights the
importance of improving the nomenclature system of






Patient details and adverse events
Acute renal failure complicating pre-
existing focal segmental glomerulosclerosis
after daily intake of herbs for 2 wk;
renal biopsy confirmed a diagnosis of
interstitial nephritis
Rapidly progressive renal failure and
bladder cancer after taking herbs for 6 mo;
renal biopsy showed hypocellular intersti-
tial nephritis
Renal failure after taking herbs for 18 mo;
renal biopsy showed interstitial fibrosis
Renal failure after taking herbs for 18 mo;
renal biopsy showed hypocellular intersti-
tial fibrosis
Underlying scleroderma and fibrosing
alveolitis; normal plasma creatinine; several
doses of herb taken over a period of 10 d
before presentation with proteinuria













18 herbs in the prescription, including
“fangi” and “mutong”; AAI and AAII
were detected in the “fangi” but not
“mutong” samples
“Baiying” was prescribed but Herba
Aristolochia Mollissemae was dispensed;
AAI was detected in the “Baiying”
sample submitted by the patient
“Baiying” was prescribed but Herba
Aristolochia Mollissemae was dispensed;
AAI was detected in the “Baiying”
sample submitted by the patient
“Baiying” was prescribed but Herba
Aristolochia Mollissemae was dispensed
Fructus Aristolochiae was prescribed;
AAI was detected in the herbal item
Table 2. Ban of aristolochic acid-containing herbs in China, Hong Kong and Taiwan
Mainland China Hong Kong Taiwan
Caulis Aristolochiae Manshuriensis !" × × ×
Radix Aristolochiae Fangchi !" × × ×
Radix Aristolochiae !" × × ×
Fructus Aristolochiae !" ✓* × ×
Herba Aristolochiae !" ✓* × ×
Herba Aristolochia Mollissemae !" ✓* × ✓
Radix Aristolochiae Cinnabarina !" ✓* × ✓
Herba Asari ! ✓ ✓† ✓†
*Should be used under the prescription of Chinese medicine practitioners; †only the root of Herba Asari can be used.
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herbs. There are different ways to name a herb: the
common name, the latinized pharmaceutical name and
the scientific name. Common names can be very loose
(Table 3). The same name can be applied to several
herbs and the same herb can have several names. This
frequently leads to substitution of one herb by another
with similar name and appearance. In China, most cases
of AAN result from the substitution of AA-containing
Caulis Aristolochiae Manshuriensis ( ) for the
herb Caulis Akebiae (). The substitution had
become routine and accepted before the risk of AA-
containing herbs was recognized [91–93]. In Hong
Kong, the substitution of Herba Solani Lyrati ()
with the AA-containing Herba Aristolochia
Mollissemae ( ) had been present for many years.
We do not know how many people have been exposed
and for how long. As the effect of poisoning can present
much later, it will take time before the true impact to
the Hong Kong community is known.
AA was known to be a carcinogen long before the
Belgian incident [13], but it took years before the risk
to the community was recognized. The AAN episode
could have been avoided or detected earlier if
surveillance programs had been more effective. Indeed,
the importance of an effective surveillance system for
adverse effects associated with herbal use, similar to
the  one  fo r  Wes te rn  med ic ine ,  canno t  be
overemphasized. Enhancement on safety measures
should go hand in hand with further developments in
TCM or other herbal products in clinical practice.
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